Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Jonathan C Strefford ,Andrew Davies,Wolfram Klapper,Chisako Iriyama,Helen Parker,Umberto Vitolo,Maurizio Martelli,Andrea Knapp,Marek Trněný,Cathy Burton,Farheen Mir,Wolfgang Hiddemann,Małgorzata Nowicka ,Matthew Rose-Zerilli ,Chantal E Hargreaves ,Kate V Latham ,Laurie H Sehn ,Kathleen Potter ,Rosalind H Ganderton ,Mark Cragg ,Mikkel Z Oestergaard

doi:10.1182/blood-2018-99-116750

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Jonathan C Strefford , Andrew Davies + Show 19 more

https://doi.org/10.1182/blood-2018-99-116750

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 3

Affiliation: University of Southampton, Cancer Research UK, Roche (Switzerland), Kiel University, Nagoya University, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Sapienza University of Rome, BC Cancer Agency, University Hospital Southampton NHS Foundation Trust, Charles University, Roche (United Kingdom), Ludwig-Maximilians-Universität München

#Advisory Committees #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Full Text